169 related articles for article (PubMed ID: 24753854)
1. Wilms' Tumour gene 1 (WT1) as an immunotherapeutic target.
Coosemans A
Facts Views Vis Obgyn; 2011; 3(2):89-99. PubMed ID: 24753854
[TBL] [Abstract][Full Text] [Related]
2. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
[TBL] [Abstract][Full Text] [Related]
3. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma.
Coosemans A; Wölfl M; Berneman ZN; Van Tendeloo V; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2010 Sep; 30(9):3709-14. PubMed ID: 20944158
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
Coosemans A; Nik SA; Caluwaerts S; Lambin S; Verbist G; Van Bree R; Schelfhout V; de Jonge E; Dalle I; Jacomen G; Cassiman JJ; Moerman P; Vergote I; Amant F
Eur J Cancer; 2007 Jul; 43(10):1630-7. PubMed ID: 17531467
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
8. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
[TBL] [Abstract][Full Text] [Related]
9. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
10. Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
Coosemans A; Moerman P; Verbist G; Maes W; Neven P; Vergote I; Van Gool SW; Amant F
Gynecol Oncol; 2008 Dec; 111(3):502-8. PubMed ID: 18929401
[TBL] [Abstract][Full Text] [Related]
11. The WT1 gene--its role in tumourigenesis and prospects for immunotherapeutic advances.
Lindstedt I; Lindgren MA; Andersson E; Engström W
In Vivo; 2014; 28(5):675-81. PubMed ID: 25189877
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.
Sera T; Hiasa Y; Mashiba T; Tokumoto Y; Hirooka M; Konishi I; Matsuura B; Michitaka K; Udaka K; Onji M
Eur J Cancer; 2008 Mar; 44(4):600-8. PubMed ID: 18255279
[TBL] [Abstract][Full Text] [Related]
14. The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo.
Wagner N; Michiels JF; Schedl A; Wagner KD
Oncogene; 2008 Jun; 27(26):3662-72. PubMed ID: 18212735
[TBL] [Abstract][Full Text] [Related]
15. Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers.
Takahashi H; Okamoto M; Shimodaira S; Tsujitani S; Nagaya M; Ishidao T; Kishimoto J; Yonemitsu Y;
Eur J Cancer; 2013 Mar; 49(4):852-9. PubMed ID: 23245331
[TBL] [Abstract][Full Text] [Related]
16. Role of the WT1 gene in Wilms' tumour.
Haber DA; Housman DE
Cancer Surv; 1992; 12():105-17. PubMed ID: 1322241
[TBL] [Abstract][Full Text] [Related]
17. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
19. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman Z; Vergote I; Amant F; Van Gool SW
Anticancer Res; 2013 Sep; 33(9):3855-9. PubMed ID: 24023319
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour.
Charles AK; Moore IE; Berry PJ
Histopathology; 1997 Apr; 30(4):312-4. PubMed ID: 9147076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
